Ratings by Barclays (Etzer Darout)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/1/2026 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2026 | Enliven Therapeutics | ELVN | New Coverage | Overweight (N/A) |
59.53 (57.86) |
-2.81% | Details | |
| 8/13/2026 | Monopar Therapeutics | MNPR | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2026 | First Tracks Biotherapeutics | TRAX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2026 | Celldex Therapeutics | CLDX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/6/2026 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/4/2026 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 7/29/2026 | Incyte | INCY | Maintain | Overweight (N/A) |
|
Details | ||
| 7/28/2026 | Forte Biosciences Inc. | FBRX | Downgrade | Equalweight (Overweight) |
54.78 (76.99) |
40.54% | Details | |
| 7/21/2026 | First Tracks Biotherapeutics | TRAX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/21/2026 | Forte Biosciences Inc. | FBRX | New Coverage | Overweight (N/A) |
48.86 (54.78) |
12.12% | Details | |
| 7/14/2026 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/14/2026 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 7/14/2026 | Incyte | INCY | Maintain | Overweight (N/A) |
|
Details | ||
| 7/14/2026 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/27/2026 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 5/13/2026 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/13/2026 | AnaptysBio | ANAB | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2026 | Scholar Rock | SRRK | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2026 | Celldex Therapeutics | CLDX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2026 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 4/27/2026 | Oruka Therapeutics | ORKA | Maintain | Overweight (N/A) |
|
Details | ||
| 4/22/2026 | AnaptysBio | ANAB | Maintain | Overweight (N/A) |
|
Details | ||
| 4/22/2026 | First Tracks Biotherapeutics | TRAX | New Coverage | Overweight (N/A) |
18.60 (41.17) |
121.34% | Details | |
| 4/20/2026 | MacroGenics | MGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/20/2026 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 4/20/2026 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/20/2026 | Tvardi Therapeutics Inc | TVRD | Downgrade | Underweight (Equalweight) |
3.22 (1.75) |
-45.65% | Details | |
| 4/20/2026 | Janux Therapeutics | JANX | Downgrade | Underweight (Overweight) |
15.19 (18.89) |
24.36% | Details | |
| 4/20/2026 | Celldex Therapeutics | CLDX | Upgrade | Overweight (Underweight) |
33.86 (39.24) |
15.89% | Details | |
| 4/1/2026 | Tvardi Therapeutics Inc | TVRD | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/30/2026 | Terns Pharmaceuticals | TERN | Downgrade | Equalweight (Overweight) |
53.17 (52.95) |
-0.41% | Details | |
| 3/24/2026 | Incyte | INCY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/24/2026 | Abivax | ABVX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/18/2026 | CytomX Therapeutics | CTMX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/18/2026 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/13/2026 | Oruka Therapeutics | ORKA | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/10/2026 | MacroGenics | MGNX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/9/2026 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2026 | AnaptysBio | ANAB | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2026 | Scholar Rock | SRRK | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2026 | Jazz Pharmaceuticals | JAZZ | New Coverage | Overweight (N/A) |
188.97 (243.71) |
28.97% | Details | |
| 2/26/2026 | C4 Therapeutics | CCCC | Maintain | Overweight (N/A) |
|
Details | ||
| 2/26/2026 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 2/26/2026 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/4/2026 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/4/2026 | CytomX Therapeutics | CTMX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/21/2026 | Rapt Therapeutics | RAPT | Downgrade | Equalweight (Overweight) |
57.57 (58.02) |
0.78% | Details | |
| 1/21/2026 | Corvus Pharmaceuticals | CRVS | Maintain | Overweight (N/A) |
|
Details | ||
| 1/20/2026 | CytomX Therapeutics | CTMX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/20/2026 | AnaptysBio | ANAB | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2025 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2025 | Scholar Rock | SRRK | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2025 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2025 | Janux Therapeutics | JANX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2025 | Celldex Therapeutics | CLDX | Maintain | Underweight (N/A) |
|
Details | ||
| 12/17/2025 | C4 Therapeutics | CCCC | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2025 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2025 | AnaptysBio | ANAB | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2025 | Summit Therapeutics plc | SMMT | Upgrade | Equalweight (Underweight) |
17.38 (14.16) |
-18.53% | Details | |
| 12/9/2025 | Terns Pharmaceuticals | TERN | Maintain | Overweight (N/A) |
|
Details | ||
| 12/9/2025 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 11/25/2025 | Terns Pharmaceuticals | TERN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/17/2025 | Scholar Rock | SRRK | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2025 | Terns Pharmaceuticals | TERN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2025 | Celldex Therapeutics | CLDX | Maintain | Underweight (N/A) |
|
Details | ||
| 11/11/2025 | AnaptysBio | ANAB | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2025 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2025 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2025 | Janux Therapeutics | JANX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2025 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2025 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2025 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/4/2025 | Terns Pharmaceuticals | TERN | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/29/2025 | Xencor, Inc. | XNCR | Upgrade | Overweight (Underweight) |
14.27 (27.91) |
95.59% | Details | |
| 10/22/2025 | Terns Pharmaceuticals | TERN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/21/2025 | Summit Therapeutics plc | SMMT | Maintain | Underweight (N/A) |
|
Details | ||
| 10/21/2025 | CytomX Therapeutics | CTMX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/20/2025 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 10/13/2025 | Tvardi Therapeutics Inc | TVRD | Downgrade | Equalweight (Overweight) |
41.60 (1.75) |
-95.79% | Details | |
| 10/13/2025 | Tvardi Therapeutics Inc | TVRD | New Coverage | Overweight (N/A) |
42.98 (41.60) |
-3.21% | Details | |
| 10/13/2025 | Rapt Therapeutics | RAPT | New Coverage | Overweight (N/A) |
30.01 (57.57) |
91.84% | Details | |
| 10/13/2025 | Oruka Therapeutics | ORKA | New Coverage | Overweight (N/A) |
25.55 (92.11) |
260.51% | Details | |
| 10/13/2025 | Monopar Therapeutics | MNPR | New Coverage | Overweight (N/A) |
100.96 (117.57) |
16.45% | Details | |
| 10/13/2025 | Corvus Pharmaceuticals | CRVS | New Coverage | Overweight (N/A) |
7.25 (14.27) |
96.83% | Details | |
| 10/13/2025 | Celldex Therapeutics | CLDX | New Coverage | Underweight (N/A) |
27.54 (39.24) |
42.48% | Details | |
| 10/13/2025 | AnaptysBio | ANAB | New Coverage | Overweight (N/A) |
31.77 (55.28) |
74% | Details | |
| 10/13/2025 | Abivax | ABVX | New Coverage | Overweight (N/A) |
90.61 (113.67) |
25.45% | Details | |
| 9/30/2025 | Merus N.V. | MRUS | Downgrade | Equalweight (Overweight) |
68.89 (90.00) |
30.64% | Details | |
| 9/23/2025 | Scholar Rock | SRRK | Maintain | Overweight (N/A) |
|
Details | ||
| 9/23/2025 | C4 Therapeutics | CCCC | Maintain | Overweight (N/A) |
|
Details | ||
| 9/22/2025 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/19/2025 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/17/2025 | Summit Therapeutics plc | SMMT | New Coverage | Underweight (N/A) |
18.94 (14.16) |
-25.24% | Details | |
| 9/17/2025 | Xencor, Inc. | XNCR | New Coverage | Underweight (N/A) |
8.49 (14.27) |
68.08% | Details | |
| 9/17/2025 | MacroGenics | MGNX | New Coverage | Overweight (N/A) |
1.56 (4.04) |
158.97% | Details | |
| 9/17/2025 | Exelixis | EXEL | New Coverage | Equalweight (N/A) |
39.01 (56.89) |
45.83% | Details | |
| 9/17/2025 | CytomX Therapeutics | CTMX | New Coverage | Overweight (N/A) |
1.99 (3.67) |
84.42% | Details | |
| 9/17/2025 | Arvinas Inc. | ARVN | New Coverage | Overweight (N/A) |
7.74 (9.28) |
19.9% | Details | |
| 9/17/2025 | Terns Pharmaceuticals | TERN | New Coverage | Overweight (N/A) |
7.13 (53.17) |
645.72% | Details | |
| 9/17/2025 | Scholar Rock | SRRK | New Coverage | Overweight (N/A) |
33.67 (55.89) |
65.99% | Details | |
| 9/17/2025 | Protagonist Therapeutics | PTGX | New Coverage | Overweight (N/A) |
0.00 (146.49) |
0% | Details | |
| 9/17/2025 | Merus N.V. | MRUS | New Coverage | Overweight (N/A) |
68.09 (68.89) |
1.17% | Details | |
| 9/17/2025 | Kymera Therapeutics | KYMR | New Coverage | Overweight (N/A) |
47.28 (119.05) |
151.8% | Details | |
| 9/17/2025 | Janux Therapeutics | JANX | New Coverage | Overweight (N/A) |
23.56 (18.89) |
-19.82% | Details | |
| 9/17/2025 | C4 Therapeutics | CCCC | Maintain | Overweight (N/A) |
|
Details |
